Oxford Biomedica

Oxford, United Kingdom
Find alternatives to Oxford Biomedica for Lentiviral →
Hybrid — also manufactures internal programs
7 confirmed programs · 3 sponsors · Last scored 2026-10-29
76.2
Signal Score
✓ FDA Inspections (2) ✓ Clinical Trials (7) ○ SEC Filings ✓ Press (20) ✓ EMA GMP (4) ✓ MHRA GMP (10) ✓ HC GMP (5)

Quick Facts: Oxford Biomedica

Signal Score
76.2/100 (as of 2026-10-29)
Quality Compliance
100.0/100 — Clean EMA record: 3 active GMP certificates (no deductions)
Headquarters
Oxford, United Kingdom
Website
Modalities
Lentiviral, AAV, Plasmid DNA
Active Programs
7 confirmed from ClinicalTrials.gov across 3 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Oxford Biomedica

Pioneer in lentiviral vector manufacturing.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
Clean EMA record: 3 active GMP certificates (no deductions)
Clean MHRA record: 10 compliant GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP, MHRA GMDP
Clean EMA record: 3 active GMP certificates (no deductions) · Clean MHRA record: 10 compliant GMP certificates (no deductions)
FDA Inspections2 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2024-06-17)
EMA GMP Certificates4 on record
MHRA GMP Certificates10 on record
Most Recent HC OutcomeCompliant · 2024-07-23
HC Attribution5 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean EMA record: 3 active GMP certificates (no deductions)
Clean MHRA record: 10 compliant GMP certificates (no deductions)
Operations 58.6
7 active programs across 3 sponsors
Modalities: AAV, Lentiviral, Plasmid DNA
6 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
7 active programs across 3 sponsors · Modalities: AAV, Lentiviral, Plasmid DNA · 6 programs in advanced phases (Phase 2/3)
Programs 7
Sponsors3
ModalitiesLentiviral, AAV, Plasmid DNA
7 active programs across 3 sponsors
Modalities: AAV, Lentiviral, Plasmid DNA
6 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT01856439 Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease PHASE1/PHASE2 Terminated
NCT01301443 Phase I Dose Escalation Safety Study of RetinoStat in... PHASE1 Completed
NCT00627588 Phase I/II Study of the Safety, Efficacy and Dose Evaluation... PHASE1/PHASE2 Completed
NCT00397345 TroVax Renal Immunotherapy Survival Trial PHASE3 Completed
NCT00445523 Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha... PHASE2 Completed
NCT00325507 Safety and Biological Activity of TroVax® Vaccine Given With... PHASE2 Completed
NCT00083941 A Study of TroVax Vaccine Given in Conjunction With IL-2 for... PHASE2 Completed
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 75.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
Capacity 58.0
1 manufacturing site: Oxford, UK
Modalities: Lentiviral, AAV, Plasmid DNA
Capacity assessment: 58.0/100
Sites: Oxford, UK
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
StatusAvailable
1 manufacturing site: Oxford, UK
Modalities: Lentiviral, AAV, Plasmid DNA
Capacity assessment: 58.0/100
Sites: Oxford, UK
Press Signals20 articles (not scored)
1 manufacturing site: Oxford, UK
Modalities: Lentiviral, AAV, Plasmid DNA
Capacity assessment: 58.0/100

Oxford Biomedica FDA Inspection History

2024-06
2024-06
NAI VAI OAI
Date Site Type 483 citations posted Classification
2024-06-17
Oxford Biomedica (UK) Limited
Oxford Company-level
Human Cellular, Tissue, and Gene Therapies Not posted No Action Indicated (NAI)
2024-06-17
Oxford Biomedica (UK) Limited
Kidlington Company-level
Human Cellular, Tissue, and Gene Therapies Not posted No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Oxford Biomedica EMA GMP Compliance 4 certificates

2024-04
2023-09
2023-09
2020-12
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
2024_HPF_FR_112 Oxford Biomedica (France) S.A.S. France 2024-04-12 COMPLIANT
2024_HPF_FR_026_ND Oxford Biomedica (France) S.A.S. France 2023-09-22 COMPLIANT
2024_HPF_FR_027_ND Oxford Biomedica (France) S.A.S. France 2023-09-22 COMPLIANT
30363/IMP12861/001 OxFord Biomedica (Ireland) Limited Ireland 2020-12-15 NON-COMPLIANT
Source: EMA EudraGMDP · Retrieved Nov 21, 2026

Oxford Biomedica MHRA GMP Compliance 10 certificates

2026-02
2026-02
2025-07
2025-07
2025-03
2025-03
2024-07
2024-07
2024-07
2024-07
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK MIA 17479 Insp GMP/IMP 17479/19229463-0009[H] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX4 2ZY 2026-02-24 COMPLIANT
UK MIA(IMP) 17479 Insp GMP/IMP 17479/19229463-0009[I] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX4 2ZY 2026-02-24 COMPLIANT
UK MIA 17479 Insp GMP/IMP 17479/19229463-0008[H] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX4 2ZY 2025-07-25 COMPLIANT
UK MIA(IMP) 17479 Insp GMP/IMP 17479/19229463-0008[I] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX4 2ZY 2025-07-25 COMPLIANT
UK MIA 17479 Insp GMP/IMP 17479/12357407-0006[H] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX5 1QU 2025-03-07 COMPLIANT
UK MIA(IMP) 17479 Insp GMP/IMP 17479/12357407-0006[I] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX5 1QU 2025-03-07 COMPLIANT
UK MIA 17479 Insp GMP/IMP 17479/12551187-0008[H] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX4 6LT 2024-07-23 COMPLIANT
UK MIA(IMP) 17479 Insp GMP/IMP 17479/12551187-0008[I] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX4 6LT 2024-07-23 COMPLIANT
UK MIA(IMP) 17479 Insp GMP/IMP 17479/285627-0009[I] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX4 6LX 2024-07-23 COMPLIANT
UK MIA 17479 Insp GMP/IMP 17479/285627-0009[H] OXFORD BIOMEDICA (UK) LIMITED OXFORD OX4 6LX 2024-07-23 COMPLIANT
Source: MHRA GMDP Database · Retrieved Nov 21, 2026

Hiring Activity 4 open roles Beta

From public job postings on Oxford Biomedica's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
4
open roles
2
in manufacturing, quality, PD/MSAT, engineering or regulatory (50%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 0 new postings, 0 taken down.
By function
Quality (QA / QC) 1
Process development & MSAT 1
Commercial, BD & client projects 1
Other (finance, HR, IT, other) 1
By site
Oxford profile site
· 2 other
2
Bedford, MA
· 1 PD/MSAT
1
Durham, NC
· 1 QA/QC
1
Notable roles
Director Quality Control Senior operations / quality role · Durham, NC
Latest postings
Director Quality Control Quality (QA / QC) · Durham, NC
Director, UK Revenue & Margin Other (finance, HR, IT, other) · Oxford
Project Programme Manager 12 month FTC Commercial, BD & client projects · Oxford
Senior Scientist, Lead Analytical Development Operations Process development & MSAT · Bedford, MA
Coverage: counted from Oxford Biomedica's own careers board. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: careers.oxb.com · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Company Signals 20 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-10-16
Oxford BioMedica Appoints Former Sartorius CEO Joachim Kreuzburg as Non-Executive Director - Yahoo Finance UK
Oxford BioMedica Appoints Former Sartorius CEO Joachim Kreuzburg as Non-Executive Director  Yahoo Finance UK
regulatory 2026-10-16
REG - Oxford Biomedica PLC - Appointment of Independent Non-Executive Director - TradingView
REG - Oxford Biomedica PLC - Appointment of Independent Non-Executive Director  TradingView
financial 2026-10-11
Oxford Biomedica (LSE:OXB) Revenue Growth and Firm Guidance Support Recovery While FTSE 100 Trades Higher - Kalkine Media
Oxford Biomedica (LSE:OXB) Revenue Growth and Firm Guidance Support Recovery While FTSE 100 Trades Higher  Kalkine Media
general 2026-10-10
Oxford Biomedica Adds LTIP Shares to London Listing - The Globe and Mail
Oxford Biomedica Adds LTIP Shares to London Listing  The Globe and Mail
general 2026-10-09
REG - Oxford Biomedica PLC - Admission to Trading - TradingView
REG - Oxford Biomedica PLC - Admission to Trading  TradingView
general 2026-10-02
REG - Oxford Biomedica PLC - Grant of Award - TradingView
REG - Oxford Biomedica PLC - Grant of Award  TradingView
general 2026-04-14
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development - The Globe and Mail
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development  The Globe and Mail
general 2026-04-13
Oxford Biomedica Launches Fast-track Viral Vector Manufacturing Service - DirectorsTalk Interviews
Oxford Biomedica Launches Fast-track Viral Vector Manufacturing Service  DirectorsTalk Interviews
general 2026-04-13
Oxford BioMedica accelerates viral vector development and manufacture - London South East
Oxford BioMedica accelerates viral vector development and manufacture  London South East
general 2026-04-13
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development - TipRanks
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development  TipRanks
general 2026-04-13
Oxford Biomedica Share News (OXB) - London South East
Oxford Biomedica Share News (OXB)  London South East
general 2026-03-31
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role - The Globe and Mail
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role  The Globe and Mail
general 2026-03-30
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role - TipRanks
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role  TipRanks
general 2026-03-30
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability - Bitget
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability  Bitget
general 2026-03-30
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability - Bitget
Oxford Biomedica’s Capital Markets Day May Spark Revaluation as Innovation Meets Profitability  Bitget
financial 2026-03-27
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge - ca.investing.com
Oxford Biomedica FY 2025 slides: CDMO turns profitable on 33% revenue surge  Investing.com Canada
general 2026-03-26
Oxford BioMedica shares fall as warns on loss-making first half - London South East
Oxford BioMedica shares fall as warns on loss-making first half  London South East
financial 2026-03-26
Earnings call transcript: Oxford Biomedica’s H2 2025 results show strong revenue growth - Investing.com
Earnings call transcript: Oxford Biomedica’s H2 2025 results show strong revenue growth  Investing.com
financial 2026-03-26
Oxford Biomedica H2 Earnings Call Highlights - Yahoo Finance
Oxford Biomedica H2 Earnings Call Highlights  Yahoo Finance
facility_expansion 2026-03-26
Oxford BioMedica Returns to Profit as U.S. Expansion and Big Pharma Deals Lift Outlook - TipRanks
Oxford BioMedica Returns to Profit as U.S. Expansion and Big Pharma Deals Lift Outlook  TipRanks

Frequently Asked Questions About Oxford Biomedica

How many FDA inspections does Oxford Biomedica have on record?
CDMO Signal tracks 2 FDA inspections for Oxford Biomedica, sourced from the FDA inspection database. See the full inspection history above.
Has Oxford Biomedica received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Oxford Biomedica.
Does Oxford Biomedica hold EMA or MHRA GMP certificates?
CDMO Signal tracks 4 EMA and 10 MHRA GMP certificates for Oxford Biomedica.
How many clinical programs is Oxford Biomedica linked to?
Oxford Biomedica is associated with 7 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Oxford Biomedica's CDMO Signal Score?
Oxford Biomedica has a Signal Score of 76/100, based on quality, operations, financial stability, and capacity data.
Evaluating Oxford Biomedica for a manufacturing program?
Use the free AI matchmaker to compare Oxford Biomedica against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Lentiviral CDMOs → AAV CDMOs → Plasmid DNA CDMOs →

Similar CDMOs

Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 77.6
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid, Small Molecule API, Oral Solid Dose, Sterile Fill-Finish
Andelyn Biosciences
Columbus, OH
Signal Score: 63.0
AAV, Lentiviral, Plasmid DNA
Advent Bioservices
London, United Kingdom
Signal Score: 78.1
AAV, Lentiviral, Adenoviral
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars

Compare Oxford Biomedica with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Oxford Biomedica
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.